Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

References

• AccordiniSCorsicoAGBraggionMThe cost of persistent asthma in Europe: an international population-based study in adultsInt Arch Allergy Immunol201316019310122948386
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaOnline Appendix – Global Strategy for Asthma Management and Prevention2018 Available from: https://ginasthma.org/2017-online-appendix-global-strategy-for-asthma-management-and-prevention/Accessed September 18, 2018
   Google Scholar
• Agency for Healthcare Research and QualityHealthcare cost and utilization project2017 Available from: https://hcupnet.ahrq.gov/#setupAccessed September 18, 2018
   Google Scholar
• Global Initiative for AsthmaGlobal Strategy for Asthma Management and Prevention2018 Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed September 18, 2018
   Google Scholar
• ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• WenzelSEAsthma: defining of the persistent adult phenotypesLancet2006368953780481316935691
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineNucala prescribing information2017 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmith-Kline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDFAccessed September 18, 2018
   Google Scholar
• Genentech USAXolair prescribing information2018 Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdfAccessed September 18, 2018
   Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet2012380984265165922901886
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• ChuppGLBradfordESAlbersFCEfficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3B trialLancet Respir Med20175539040028395936
   PubMed Web of Science ®Google Scholar
• BusseWCorrenJLanierBQOmalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJ Allergy Clin Immunol2001108218419011496232
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
   PubMed Web of Science ®Google Scholar
• HananiaNAAlpanOHamilosDLOmalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trialAnn Intern Med2011154957358221536936
   PubMed Web of Science ®Google Scholar
• YanceySWOrtegaHGKeeneONMeta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthmaJ Allergy Clin Immunol2017139411671175.e227726946
   PubMed Web of Science ®Google Scholar
• CorrenJCasaleTDenizYAshbyMOmalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthmaJ Allergy Clin Immunol20031111879012532101
   PubMed Web of Science ®Google Scholar
• CockleSMStynesGGunsoyNBComparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparisonRespir Med201712314014828137490
   PubMed Web of Science ®Google Scholar
• NachefZKrishnanAMashtareTZhuangTMadorMJOmalizumab versus mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-analysisJ Asthma20185518910028459601
   PubMed Web of Science ®Google Scholar
• AlbersFCLiuMCChippsBEEfficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomesJ Allergy Clin Immunol20181412AB408
   Google Scholar
• GalkinDLiuMCChippsBEEfficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomesJ Allergy Clin Immunol20181412AB409
   Google Scholar
• SurukiRYDaughertyJBBoudiafNAlbersFCThe frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USABMC Pulm Med20171717428449686
   PubMed Web of Science ®Google Scholar
• BhutaniMYangWHHébertJde TakacsyFStrilJLThe real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational studyPLoS One2017128e018386928859150
   PubMed Web of Science ®Google Scholar
• KarpelJMassanariMGebaGPKianifardFInhaberNZeldinRKEffectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthmaAnn Allergy Asthma Immunol2010105646547021130385
   PubMed Web of Science ®Google Scholar
• AlbersFCMüllerováHGunsoyNBBiologic treatment eligibility for real-world patients with severe asthma: the IDEAL studyJ Asthma201855215216028622052
   PubMed Web of Science ®Google Scholar
• ShahSAIshinagaHTakeuchiKPathogenesis of eosinophilic chronic rhinosinusitisJ Inflamm (Lond)20161311127053925
   PubMed Web of Science ®Google Scholar
• TashkinDPWechslerMERole of eosinophils in airway inflammation of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20181333534929403271
   PubMed Web of Science ®Google Scholar
• LiuMHumbertMBrattonDEffect of mepolizumab (100 mg subcutaneous) on exacerbation rate in patients with severe eosinophilic asthma by omalizumab eligibility (US criteria), and immunoglobulin E and eosinophilic subgroupsAm J Respir Crit Care Med2018197A7657
   Google Scholar
• MagnanABourdinAPrazmaCMTreatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatmentAllergy20167191335134427087007
   PubMed Web of Science ®Google Scholar
• GenentechFDA Approves Xolair, biotechnology breakthrough for asthma2003 Available from: https://www.gene.com/media/press-releases/6287/2003-06-20/fda-approves-xolair-biotechnology-breaktAccessed September 18, 2018
   Google Scholar
• GlaxoSmithKlineGSK’s Nucala (mepolizumab) receives approval from US FDA2015 Available from: https://us.gsk.com/en-us/media/press-releases/2015/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/Accessed September 18, 2018
   Google Scholar